Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment
Open accessThe DOI matches its Crossref record; 167 of the 169 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Head and neck cancers rank sixth among the most common cancers today, and the survival rate has remained virtually unchanged over the past 25 years, due to late diagnosis and ineffective treatments. They have two main risk factors, tobacco and alcohol, and human papillomavirus infection is a secondary risk factor. These cancers affect areas of the body that are fundamental for the five senses. Therefore, it is necessary to treat them effectively and non-invasively as early as possible, in order to do not compromise vital functions, which is not always possible with conventional treatments (chemotherapy or radiotherapy). In this sense, nanomedicine plays a key role in the treatment and diagnosis of head and neck cancers. Nanomedicine involves using nanocarriers to deliver drugs to sites of action and reducing the necessary doses and possible side effects. The main purpose of this review is to give an overview of the applications of nanocarrier systems to the diagnosis and treatment of head and neck cancer. Herein, several types of delivery strategies, radiation enhancement, inside-out hyperthermia, and theragnostic approaches are addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 4 Drug delivery systems’ strategies for anticancer therapy: passive targeting and active targeting. Adapted with permission from [76].](https://figures.cochat.ai/paper-figures/5de7a8b810484466979d8b5ee5511140/insights-into-nanomedicine-for-head-and-neck-cancer-diagnosis-and-treatment-figure-4.jpg)




![Figure 6 Alterations in tumor growth over 5 weeks of treatment in 6 distinct groups of rats to study ways to overcome tumor radioresistance by increasing absorbed radiation in clinically relevant energy dosages using cetuximab carried by gold nanoparticles. Reprinted with permission from [125].](https://figures.cochat.ai/paper-figures/1230d0fdc467476ba4518a6917c4fc40/insights-into-nanomedicine-for-head-and-neck-cancer-diagnosis-and-treatment-figure-6.jpg)
![Figure 7 Nanotechnology in local hyperthermia: The nanoparticles are accumulated inside the tumor and are capable of absorbing energy from various external heat sources, thereby potentiating the effects of hyperthermia. On the right, in comparison with the left, it is possible see the effect that the nanoparticles have on heat in the tumor site. Nanoparticles focus the energy from the external source on the tumor to induce localized thermal destruction while minimizing the adverse effects on collateral tissues. Abbreviations: NPTT: nano-photo-thermal therapy. NMH: nano-magnetic hyperthermia. NaRFA: nano-radio-frequency ablation. NUH: nano-ultrasound hyperthermia. Reprinted with permission from [141].](https://figures.cochat.ai/paper-figures/2e455e94f080409cbb3c8681602eeaf5/insights-into-nanomedicine-for-head-and-neck-cancer-diagnosis-and-treatment-figure-7.jpg)
![Figure 8 Platelet-facilitated photothermal tumor therapy (PLT-PTT): Platelets (PLTs) after isolation in the blood were mixed with gold nanorods (AuNRs), which after an electroporation process, were taken up by the PLTs. The resulting AuNR-loaded PLTs (PLT-AuNRs) reached the tumor cells using in vivo photothermal tumor therapy (PTT). Reprinted with permission from [102].](https://figures.cochat.ai/paper-figures/463057db844e4cd48758498fc5367b30/insights-into-nanomedicine-for-head-and-neck-cancer-diagnosis-and-treatment-figure-8.jpg)
![Figure 9 Quadrapeutic strategy in cancer treatment: Systemic administration of gold colloids conjugated with antibodies and liposomal drugs to form nanoclusters in cancer cells; local application of a laser pulse through an endoscope to selectively generate plasmonic nanobubbles (PNBs) in cancer cells; selective amplification of radiation by the nanocluster in cancer cells. Reprinted with permission from [161].](https://figures.cochat.ai/paper-figures/44bfb390343d489c80478a1e53bd49c6/insights-into-nanomedicine-for-head-and-neck-cancer-diagnosis-and-treatment-figure-9.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, these formulations, often designed for multifunctionality, allow for the simultaneous delivery of therapeutic agents, contrast agents, or even multiple radionuclides, showcasing remarkable flexibility and synergistic therapeutic potential [65].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [65]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · cited 4×
“Head and neck cancer (HNC) is a complex and heterogeneous disease that encompasses a large number of cancer cell locations and is considered a leading cause of cancer death worldwide [4,6].”
BackgroundInfluentialNanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“We would also like to see governments backing their scaled-up production, which will also their approval beforehand [48,166].”
BackgroundLiposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“However, it was Gregory Gregoriadis who established the concept of drug encapsulation in liposomes [112,113].”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“Concerning the pharmacokinetics, biodistribution, and residence times of nanocarriers in the body, it was found that their biopersistence is high and that sometimes problems arise in their clearance, making these aspects also reliant on the design and development of such systems [167,171].”
BackgroundTherapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920 · cited 2×
“With certain materials/structures, this mechanism can avoid recognition by the P-glycoproteins [67,84].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824 · cited 3×
“In this sense, to personalize the therapeutic approach to be taken with each user, it is essential to understand the biological mechanisms related to the distribution and retention of nanocarriers in tumors [48,71].”
BackgroundNanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586 · cited 1×
“Additionally, it is important to know their interactions with organ and biomarker systems in vivo [168].”
BackgroundChithrani, B. D., & Chan, W. C. W. (2007) · Nano Letters · doi:10.1021/nl070363y · Cited by 2,286 · cited 1×
“On the other hand, Au nanoparticles internalized in cells are also not easily eliminated, although there is some evidence for size-dependent exocytosis [167,173,174].”
BackgroundArgiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Research works printed but not linked: 5
- Mooore, K.L., Dalley, A.F., and Agur, A.M.R. (2017). Moore Clinically Oriented Anatomy, Wolters Kluwer India Pvt Ltd.
- Caban, 2014, Nanosystems for drug delivery, OA Drug Des. Deliv., 2, 1
- Niemirowicz, 2012, Nanocarriers in modern drug delivery systems, Chemik, 66, 868
- Ruba, 2018, Radiosensitizers and radioprotectors for effective radiation therapy—A review, Asian J. Appl. Sci. Technol., 2, 77
- Butterworth, 2010, UKPMC Funders Group nm gold particles: Potential application for cancer therapy, Evaluation, 21, 295101
Cited by
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“Moreover, these formulations, often designed for multifunctionality, allow for the simultaneous delivery of therapeutic agents, contrast agents, or even multiple radionuclides, showcasing remarkable flexibility and synergistic therapeutic potential [65].”
BackgroundBharath, G., Sabri, M. A., Hai, A., BANAT, F. A., & Haija, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030868 · Cited by 118
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
Viegas, C., Patrício, A. B., Prata, J., Fonseca, L., Macedo, A. S., Duarte, S. O. D., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092363 · Cited by 50
Self-citationQureshi, M., Viegas, C., Duarte, S. O. D., Girardi, M., Shehzad, A., & Fonte, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124340 · Cited by 24
Self-citationNanotheranostics-based Management of Head and Neck Cancer
Chavda, V. P., Balar, P. C., & Patel, S. B. (2023) · Nanotheranostics · doi:10.7150/ntno.81724 · Cited by 28
Metadata
- Authors
- Viegas, C., Pereira, D. S. M., & Fonte, P.
- Affiliations
- Centro de Ciências do Mar do Algarve (PT)
- University of Minho (PT)
- University of Lisbon (PT)
- Corresponding author
- Fonte, Pedro
- Venue
- Materials
- Publisher
- MDPI AG
- Published
- 2022-03-11
- Volume
- 15
- Issue
- 6
- Pages
- 2086
- ISSN
- 1996-1944 (ISSN-L)
- PMC
- PMC8951645
- OpenAlex
- W4221071836
- Cited by
- 21
- References
- 169
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 1
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Materials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- Fundação para a Ciência e Tecnologia (UIDB/04326/2020, UIDB/04565/2020, UIDP/04565/2020, LA/P/0140/2020, 2020.08839.BD)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- head and neck cancer, nanomedicine, nanocarriers, drug delivery, cancer diagnosis, radiation enhancement, theranostics, non-invasive treatment, human papillomavirus, tobacco and alcohol risk factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment. https://app.cochat.ai/papers/10.3390/ma15062086
- The paper
- Viegas, C., Pereira, D. S. M., & Fonte, P. (2022). Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment. Materials. https://doi.org/10.3390/ma15062086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.